CCA
SION

Cygnus Capital Advisors’s Sionna Therapeutics SION Stock Holding History

Cygnus Capital Advisors’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$152 Buy
3,800
+1,400
+58% +$53.4K 0.1% 54
2025
Q4 		$99 Buy
+2,400
New +$91K 0.07% 59

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cygnus Capital Advisors's SION Position: Q1 2026 in Review

Cygnus Capital Advisors increased its Sionna Therapeutics (SION) stake by 58% in Q1 2026, buying an estimated $53.4K and bringing the position to 3,800 shares worth $152. The position accounts for 0.1% of the portfolio, ranked #54.

Cygnus Capital Advisors first reported a position in SION in Q4 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Cygnus Capital Advisors held 3,800 shares of Sionna Therapeutics worth $152 as of Q1 2026.
  • Cygnus Capital Advisors bought 1,400 Sionna Therapeutics shares in Q1 2026, an estimated $53.4K.
  • Sionna Therapeutics made up 0.1% of Cygnus Capital Advisors's portfolio in Q1 2026, its #54 holding.
  • Cygnus Capital Advisors first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.